In this episode of the Nervennahrung podcast, Prof. Mathias Mäurer hosts Alzheimer's expert Prof. Thomas Duning to discuss the significant recent advancements in the diagnosis and treatment of Alzheimer's disease. The conversation highlights a paradigm shift in diagnostics, moving towards early detection through essential biomarkers like amyloid and tau proteins, primarily analyzed from cerebrospinal fluid. Prof. Duning emphasizes the imminent arrival of highly accurate, non-invasive blood-based tests (specifically for p-tau217) that promise to revolutionize early diagnosis. The discussion then turns to new anti-amyloid antibody therapies, Lecanemab and Donanemab, which are approved in the US and have shown a significant, though not curative, effect in slowing disease progression. Key challenges are detailed, including the management of the primary side effect, ARIA (Amyloid-Related Imaging Abnormalities), which necessitates regular MRI monitoring, and critical contraindications for patients on anticoagulants or those with a homozygous ApoE4 genetic profile. The podcast concludes by outlining the future structure of patient care, envisioning a network of specialized memory clinics, and offering practical advice for healthy cognitive aging.
Navigating Alzheimer's Breakthroughs: Insights on Diagnosis and Emerging Therapies
2:49 A New Era in Diagnostics: The approach to Alzheimer's diagnosis has fundamentally changed. It now relies on early detection using biological markers (amyloid and tau proteins), making biomarker analysis from cerebrospinal fluid (CSF) a standard part of a guideline-compliant diagnosis.
4:24 The Clinical Screening Process: Before advanced testing, a clinical assessment is crucial. This includes simple bedside tests for memory (three-word recall), visuospatial skills (clock-drawing test), and praxis (gestures), often supplemented by a standardized screening tool like the MOCA test.
6:52 The Future is in the Blood: Invasive CSF collection may soon be replaced. New studies show that blood-based biomarkers, particularly phosphorylated Tau (p-tau217), are exceptionally accurate for detecting brain amyloid pathology and are expected to become widely available, simplifying early diagnosis.
9:25 Breakthrough Antibody Therapies: Lecanemab and Donanemab are new anti-amyloid antibodies, approved in the U.S., that effectively clear amyloid plaques from the brain. While not a cure, they demonstrably slow the course of the disease in its early stages.
15:48 Lecanemab vs. Donanemab: The two antibodies have a key practical difference. Donanemab is administered via intravenous infusion every four weeks, offering more convenience than Lecanemab, which requires infusion every two weeks.
18:21 Managing Serious Side Effects: The primary side effect of these antibodies is ARIA (Amyloid-Related Imaging Abnormalities), an inflammatory response in the brain visible on MRI. While often asymptomatic, it requires regular MRI monitoring to manage the risk of brain swelling and microhemorrhages.
19:46 Key Patient Exclusions: Due to an elevated risk of brain hemorrhage, these new therapies are not suitable for everyone. Patients on anticoagulants and those with a specific genetic profile (homozygous for ApoE4) will likely be excluded from treatment in Europe.
21:01 The Future of Patient Care: The complexity of these new treatments necessitates a restructured healthcare model, involving a network of specialized "memory clinics" for initial diagnosis and therapy, working in tandem with local neurologists for ongoing care and monitoring.
24:23 Tips for Healthy Cognitive Aging: Prof. Duning advises that practical steps are more important than extreme "self-optimization." Key recommendations include staying socially active, correcting hearing and vision loss with aids, and avoiding head injuries.